Advancing Science Across Regenerative Medicine and Rare Disease

Triovance develops targeted therapies for conditions with serious unmet needs. From diabetic foot ulcers to rare genetic disease.

Pipeline

Stay up to date on the status of all our treatments currently in development.

Late preclinical. A genetically engineered skin graft that cures diabetic foot disease from within.

An oral ALPK1 inhibitor for a rare, serious genetic disease, developed by Triovance.